Potassium supplementation and heart rate: A meta-analysis of randomized controlled trials

L Gijsbers1, F J M Mölenberg2, S J L Bakker3

  • 1Top Institute Food and Nutrition, Wageningen, The Netherlands; Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands.

Insights

Increasing dietary potassium intake does not significantly affect heart rate (HR) in healthy adults. This meta-analysis found no overall effect or dose-response relationship for potassium supplementation on HR.

Area of Science:

  • Cardiovascular Health
  • Nutritional Science
  • Clinical Trials

Background:

  • Potassium intake is known to reduce blood pressure.
  • The impact of potassium on heart rate (HR) remains largely uninvestigated.
  • This study addresses the unknown effects of potassium supplementation on HR.

Purpose of the Study:

  • To assess the effect of increased potassium intake on heart rate (HR).
  • To conduct a meta-analysis of randomized controlled trials evaluating potassium supplementation and HR.
  • To explore potential dose-response relationships and subgroup effects.

Main Methods:

  • Systematic search of PubMed and reference lists for relevant randomized, placebo-controlled trials.
  • Inclusion criteria: healthy adults, minimum two-week duration, assessed potassium's effect on HR.
  • Data extraction by two independent investigators; random effects meta-analyses, subgroup, and meta-regression analyses were performed.

Main Results:

  • Twenty-two trials with 1086 subjects were included, with median potassium dose of 2.5 g/day and median intervention duration of 4 weeks.
  • The meta-analysis revealed no significant overall effect of increased potassium intake on heart rate (0.19 bpm; 95% CI: -0.44, 0.82).
  • Stratified analyses and meta-regression showed no significant effects in subgroups or evidence of a dose-response relationship.

Conclusions:

  • Chronic increase in potassium intake (2-3 g/day) is unlikely to alter heart rate in apparently healthy adults.
  • Supplemental potassium does not appear to be a significant factor in modulating heart rate.
  • Further research may be warranted for specific populations or higher doses.
Abstract

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.6K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
514
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K